If clinicians know in advance which drugs will work for individual patients, they can eliminate trial-and-error prescribing, decrease costs, and improve outcomes. Part 1 of a three-part series reviews the history, barriers, and outlook of this emerging practice.
You are here
P&T® Journal contents for October 2010
Part 1: Evolution and Development into Theranostics
A Concise Case Report and Literature Review
The case of a 23-year-old African-American woman who underwent live donor kidney transplantation illustrates the complexity of drug interactions involving the cytochrome P450 system.
Part 3: Policies and Practices Regarding Dietary Supplements In Health Care Facilities
Despite the increased acceptance of CAM and integrative medicine, many inpatient institutions have not established formal policies concerning their use. In the final article of this series, the challenges of integrating CAM (such as what to do about patients bringing dietary supplements into the hospital) are discussed.
Topics include aliskiren/amlodipine (Tekamlo) tablets for hypertension, bimatoprost ophthamic solution (Lumigan 0.01%) for glaucoma, and hexaminolevulinate HCl (Cysview Solution) for the detection of bladder cancer.
Selected sessions address antiplatelet therapies for acute coronary syndrome and cardiac and stroke risk reduction in patients with heart failure and atrial fibrillation.